+376.7%
AMD vs MRNA
+30.4%
+346.3%
-63.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.9% | -3.6% | +9.5% | +6.1% |
| 7D | +10.0% | -9.0% | +19.1% | +10.5% |
| 30D | +4.6% | +137.2% | -132.5% | -4.9% |
| 3M | +3.1% | +194.8% | -191.7% | -12.0% |
| 6M | +162.8% | +167.2% | -4.4% | +128.8% |
| YTD | +136.2% | +375.9% | -239.7% | +82.6% |
| 1Y | +234.0% | +465.2% | -231.1% | +147.1% |
| 3Y | +376.7% | +30.4% | +346.3% | +319.9% |
| All | +376.7% | +30.4% | +346.3% | +319.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling